MOTS-c AND SLU at the same time?

Hong Kong Yanpep International
Running both at once is viable but makes it harder to isolate what's driving adaptation - if budget isn't the issue, the combination makes sense; if it is, MOTS-C first gets the mitochondrial baseline before adding the exercise mimetic.
 
the AMPK-mTOR antagonism is the reason MOTS-c and compounds that work through mTOR activation make less sense to run simultaneously - the pathways are pulling in opposite directions. stacking MOTS-c with SLU-PP-332 is different because they hit separate mitochondrial targets, which is why the combined approach makes mechanistic sense when the goal is both metabolic flexibility and energy output
 
the mitochondrial health dependency for MOTS-c is the piece that explains a lot of the no-effect reports - the compound works through the AMPK signaling pathway, but that pathway requires baseline mitochondrial function to produce any downstream benefit. people with existing mitochondrial dysfunction from metabolic syndrome, poor sleep, or other factors may not see the expected response until those upstream conditions improve
 
Back
Top